Rapid desensitization to methotrexate a successful case in acute lymphoblastic leukemia

Main Article Content

Rosa Ivett Guzmán Avilán https://orcid.org/0000-0002-9850-9360
Natalhie Acuña Ortega https://orcid.org/0000-0002-4190-5389
Sandra Nora González Díaz https://orcid.org/0000-0002-3612-0042
Cindy Elizabeth De Lira Quezada https://orcid.org/0000-0002-6692-8130
Ana Karen Chávez Ruiz https://orcid.org/0000-0001-5145-9143
Danna Sofia Ríos González https://orcid.org/0009-0006-5757-7830

Keywords

Acute-lymphoblastic-leukemia, Allergy-management , Drug-hypersensitivity , Methotrexate, Rapid-desensitization

Abstract

Methotrexate (MTX) is a folate antimetabolite indicated for the treatment of malignant and autoimmune diseases. It is one of the most effective drugs used for the treatment and maintenance therapy of acute lymphoblastic leukemia (ALL). This paper presents a 13-year-old patient with B-type ALL who experienced a severe hypersensitivity reaction, prompting the implementation of a MTX desensitization protocol. This protocol may serve as a useful reference for future desensitization procedures. This case challenged the medical team in determining how to safely continue with the prescribed therapy. Although cases of MTX desensitization have been published in the literature, most of these are adult patients; only a few were pediatric patients; and even a fewer were patients with ALL. Given the absence of alternative treatment options, MTX desensitization was implemented, leading to a successful continuation of the therapy.

Abstract 0 | PDF Downloads 0 XML Downloads 0 HTML Downloads 0

References

1. Dilley MA, Lee JP, Broyles AD. Methotrexate hypersensitivity reactions in pediatrics: Evaluation and management. Pediatr Blood Cancer 2017;64(5):e26306. https://doi.org/10.1002/pbc.26306
2. Vázquez-Cornejo E, Morales-Ríos O, Hernández-Pliego G, Cicero-Oneto C, Garduño-Espinosa J. Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico. PLoS One. 2022;17:e0265450. https://doi.org/10.1371/journal.pone.0265450
3. Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ, et al. Practical guidance for the evaluation and management of drug hypersensitivity: Specific drugs. J Allergy Clin Immunol Pract. 2020;8(9):S16–S116. https://doi.org/10.1016/j.jaip.2020.08.006
4. Akaihata M, Miyata K, Shimomura Y, Hori T, Okumura A. Hypersensitivity reaction to high-dose methotrexate and methotrexate-induced acral erythema in a child with acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 2022;60:264–8. https://doi.org/10.5414/CP204143
5. Zafra H. Methotrexate desensitization and tolerance [Internet]. Authorea, 2022. Available from: https://doi.org/10.22541/au.165035702.26560952/v2.
6. Cernadas J, Vasconcelos MJ, Carneiro-Leão L. Desensitization in children allergic to drugs: Indications, protocols, and limits. Pediatr Allergy Immunol. 2023;34:e13965. https://doi.org/10.1111/pai.13965
7. Caldeira T, Costa V, Silva I, Belém LC, Antunes AM, Medeiros F, et al. Anaphylactoid reaction to high-dose methotrexate and re-administration after successful desensitization. Pediatr Hematol Oncol. 2008 May;25(4):347–53. https://doi.org/10.1080/08880010802019861
8. Oulego-Erroz I, Maneiro-Freire M, Bouzón-Alejandro M, Rodríguez-Núñez A, Cid-González R, Castro-Gago M. Anaphylactoid reaction to high-dose methotrexate and successful desensitization. Pediatr Blood Cancer. 2010 Apr;54(4):613–5. https://doi.org/10.1002/pbc.22358
9. Kohli A, Ferencz TM, Calderon JG. Readministration of high-dose methotrexate in a patient with suspected immediate hypersensitivity and T-cell acute lymphoblastic leukemia. Allergy Asthma Proc. 2004;25(4):249–52. PMID: 15510585
10. Scott JR, Ward DA, Crews KR, Navid F. Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma. Pediatr Blood Cancer. 2014 Jan;61(1):185–6. https://doi.org/10.1002/pbc.24683